Medicinal Plants in the Treatment of Depression: Evidence from Preclinical Studies

Introduction

Depression is a syndrome characterized by profound sadness and a global inhibition of psychic functions. It is also the most common mental alteration among the general population, affecting about 322 million people worldwide [1]. It is estimated that the number of people living with depression increased by roughly 18% between 2005 and 2015, making it one of the great epidemics of the 21st century [2]. Depression manifests itself as sadness, hopelessness, apathy, and anhedonia, with feelings of worthless-
ness or excessive guilt, insomnia or hypersomnia, significant weight loss or—contrarily—hyperphagia, cognitive alterations such as a diminished ability to concentrate, and often recurrent suicidal ideation [3]. The standard recommended treatment for depression often combines both psychological and pharmacological therapies (sometimes including brain stimulation) to manage the disease, but lack of adherence to treatment is frequent, mainly due to adverse reactions. According to the STAR*D trial document, undesirable effects have become a serious problem in psychiatry, affecting about 30% of patients [4]. In addition, both the numerous difficulties in accessing proper treatment and the high number of patients who do not respond to pharmacological treatments (approximately 40%) constitute significant barriers to a good treatment outcome [5]. Taken together, these factors have driven many people to focus on complementary and alternative medicines to try to avoid the common side effects of standard pharmacological treatment for depression [1,6]. This search for alternative approaches has led to an increased interest in herbal remedies; indeed, a broad range of medicinal plants are currently being tested for their potentially therapeutic effects in response to patients’ demands. That being said, there are many more studies conducted as preclinical rather than clinical trials.

Our literature search revealed approximately 650 papers evaluating the effects of medicinal plants with promising potential in the treatment of general mood disorders, particularly major depressive disorder. Surprisingly, to the best of our knowledge, no literature review providing a comprehensive understanding of whether these drugs produce real benefits and which biomolecular mechanisms of action are involved has been published to date.

The purpose of this narrative systematic review is to provide an update regarding those medicinal plants that have been studied from 2000 to the present and which have been found to have some type of therapeutic potential in the treatment of depression or affective disorders, especially curcumin and saffron, which are the most frequently evaluated plant species in both preclinical and clinical studies. For this review, we compiled all articles published in English in peer review journals and cited in the Cochrane Library, PubMed, Scopus, and Web of Science databases; the timespan comprises the period from the year 2000 to March 2020. We have focused on preclinical evidence for medicinal plants with antidepressant-like activity. The key words employed for this review were “depression”, “antidepressant”, “medicinal plants”, “in vivo antidepressant test”, and “in vitro antidepressant test”. For this preclinical review, the criteria of inclusion were that first, the studies included a standardized test, such as the FST and/or the TST, and second, that they included the concept of CUMS in animal models or a specific in vitro test, for example, studies on
neurotransmitters implicated in depression as well as their metabolic and signal pathways. Thus, the aim of this review is not only to find out which medicinal plants have potential antidepressant-like effects but also to ascertain the potential mechanisms of their active principles.

Possible Mechanisms of Action for Antidepressant Agents

The monoaminergic hypothesis is the classic explanation and most widely accepted molecular mechanism for the etiology of depression; as such, most pharmacological agents used to treat the disease target this pathway. The existing relationship between the physiological disturbances observed in depression and neurotransmitter activity—principally NA, 5-HT, DA, and HPA axis activity—along with oxidative and nitrosative stress and mitochondrial activity seems clear [7–11], although the relationship with other biochemical phenomena remains less so. This uncertainty has given rise to a certain urgency to test alternative hypotheses. In response, various studies have observed a relationship between depression and inflammation, thereby increasing interest in the roles of IL-6, TNF-α, and C-reactive protein in depression, as well as in their potential as targets in the treatment of the disease [7–9]. A decrease in NO levels (elevated in patients with major depression) [11], possibly through the inhibition of iNOS, as well as the activity of nNOS in humans, could help to modulate the production of neurotransmitters such as NA [12]. In the case of oxidative stress, one of the mechanisms for evaluating active compounds examines their effects on either the oxidative enzymes or Nrf2 involved in the expression of different genes, including those for antioxidant enzymes [12]. Other studies have found that depressive patients also usually present with altered mitochondrial membrane depolarization, which shows up as oxidized mitochondrial DNA, promoting high levels of central and peripheral ROS. In the brain, the effects of ROS, which are mainly due to peroxidation, are well established and involve neuronal damage, apoptosis, protein and DNA injury, reduced antioxidant defenses, and, of course, neuroinflammation. These facts have recently been discussed in an extensive review regarding the association between inflammation, mitochondrial dysfunction, and oxidative stress [5]. Taking all these data into account, medicinal plants may have a relevant role in the search for and development of new therapeutic approaches for the treatment of depression, especially for drug-resistant patients or those who suffer adverse side effects.

Medicinal Plants as Antidepressant-like Agents

Many medicinal plants have long been used in both folk medicine and phytotherapies for pathologies of the CNS, although most of them have not been evaluated in clinical trials. The ethnopharmacological use of these plants has led to a selection of several of them for clinical use after prior evaluation at the experimental level. Indeed, of the approximately 660 reports of “antidepressant medicinal plants” in PubMed, 183 have been included in this review, with a relevant number yielding positive results. Table 1S (Supplementary Information) provides a list of 155 species described or studied as either potential antidepressant agents or sources of active principles.

The main animal-specific protocols to test the efficacy of medicinal plants as antidepressant drugs are methods such as the FST, TST, and CUMS, which are then complemented with other instruments such the OFT or the EPM [13]. The FST or behavioral despair test, in which the mouse strain is of high interest, is one of the most used tools for screening antidepressants [14, 15] as it has both good reliability and predictive validity. The TST protocol is similar to that of the FST, except that mobility is impaired by suspending the test animal’s tail. This test is especially useful as a tool in drug discovery for high-throughput screening of prospective antidepressant compounds [16–18]. In the case of CUMS, it is commonly used as a reliable and effective rodent model of depression, but is often difficult to reproduce in different laboratory settings, making it unsuitable as a standard method of testing [19]. These tests are frequently complemented with the OFT and EPM, which are used for measuring anxiety-like behavior; however, they are of ancillary interest in diseases such as major depression [20–22]. Still, various problems for evaluating the effects of medicinal plants exist, primarily the use of different solvents to obtain the extract (ethanol, methanol, water, or other solvents), choosing which vegetal organ to study (roots, leaves, stems), or the use of enriched extract (e.g., enriched in terpenoids, saponins, flavonoids, or other phenolics, among others).

The selected papers are compiled in Table 1S (Supplementary Information); some have already been cited in previous reviews [23–31]. The table includes the botanical and family name, common denomination, tests performed, part of plant tested, extraction solvent, doses, via of administration, possible mediators implicated, and references for each plant. These data are thus not included in the text. The names of the botanical species have been updated according to the latest revision of “The Plant List: A working list of all known plant species” [32].

Experimental Studies in Animals or Cells

* Aconitum carmichaelii* contains alkaloids and polysaccharides as active principles. While the polysaccharide fraction had no effect on brain monoamine levels in the frontal cortex, it did increase the expression of BDNF in the brains of mice, as well as the number of dentate gyrus neurons [33]. In the case of the alkaloid fraction, it was shown to enhance the ratio of phosphorylated-CREB and BDNF protein levels in the frontal cortex and hippocampus in ovarietomized mice. Unfortunately, the 8-acetyl,14-benzoyl diester diterpene alkaloids are highly toxic; however, during the preparation process (decoction), the toxic diester alkaloids can be hydrolyzed into less toxic monoester aconitine alkaloids, which can then be converted to even less toxic aconine alkaloids with no observable reduction in pharmacological activity [34].

Both the essential oil and the water extract of *Acorus calamus* var. angustatus shows antidepressant-like effects in the FST and TST, but not in the OFT [35–37]. Using these same tests, Han et al. [35] demonstrated that the essential oil from the rhizomes of the plant, along with its major compounds, principally β-asarone (47, Fig. 6S, Supplementary Information), exert antidepressant-like effects. Similar conclusions were obtained by Dong et al.
[36], who assayed β-arson and in a CUMS model and found that this compound significantly increased the expression of BDNF at both the transcription and translation levels. With regard to the mechanism of action, this compound acts in a stress-dependent manner to block ERK1/2-CREB signaling but exhibited no effects in nonstressed rats. In a subsequent study, Zang et al. [37] observed similar effects for the petroleum ether and water fractions, demonstrating that even water fractions with only trace amounts of β-arson exert antidepressant-like effects. The active extract contains different phenolics with the activity due to the regulation of SERT activity [37].

_Acta cimicifuga_ reduced immobility duration in both the FST and TST without affecting locomotor activity, enhanced the 5-hydroxytryptophan-induced head-twitch response, decreased the levels of plasma ACTH, and lowered serum corticosterone and adrenal gland weight in CUMS-treated female rats. Both serotoninergic and noradrenergic activation are implicated in the effects as well as the normalization of the HPA axis [38]. A related plant, _Actaea racemosa_ is traditionally used for ameliorating premenstrual and dysmenorrheic disorders as well as neurovegetative climacteric complaints. Winterhoff et al. [39] tested the standardized BNO 1055 extract using a TST and observed a significant decrease in the period of immobility along with a reduction in the frequency of hot flashes, a result that is in agreement with the therapeutic responses in climacteric women [39]. _Aegle marmelos_ was analyzed for its potential antidepressant-like effect with a TST as well as with the EPM as an anxiolytic test. While the extract showed demonstrable effects in the TST, its activity was significantly decreased by the α1 and D2 antagonists, as well as by the GABA_α_ agonist, thus implying the involvement of the adrenergic and dopaminergic systems [40]. The antidepressant-like mechanism of _Agapanthus campanulatus_ was tested in vitro with a functional uptake inhibition assay against SERT, NAT, and DAT. The ethanolic extract demonstrated dose-dependent antidepressant-like effects in the FST and TST while inhibiting SERT, NAT, and DAT [41, 42]. Likewise, _Akebia quinata_ was shown to decrease immobility in both the FST and TST in mice and reversed CUMS-induced inhibition of sucrose consumption in rats. The effects were associated with decreased levels of plasma ACTH and serum corticosterone in CUMS-rats [43]. Jing et al. [44] established that heraderagenin (1, Fig. 1S, Supplementary Information) was the principal active compound, finding that it inhibited SERT, NAT, and DAT in rat brain membrane preparations and HEK293 cells transfected with the corresponding human SERTs. Hederagenin increased both NA and 5-HT levels as well as the expression of 5-HT _1A_ receptor mRNA, while decreasing the expression of the mRNAs for NAT and DAT and affecting the expression of BDNF [45]. _Allophila multiflora_ showed positive effects in both the anxiolytic (EPN, OFT) and antidepressant tests (FST) in rats and mice but had no effect on locomotor activity. The researchers suggested the implication of monoamine systems but could not establish their involvement [46]. The antidepressant and anxiolytic effects of _Allium macrostemon_ (water extract) were investigated with the EPM [47] while the methylene chloride fraction was assayed with the TST [48]. In the first case, an increase was noted in both time spent and arm entries, whereas in the latter test, the fraction reduced the immobility time compared to the control group [47]. This antidepressant-like effect was reversed by treatment with a 5-HT _1A_ receptor antagonist but was not affected by treatment with 5-HT _1B_ or 5-HT _2A_ receptor antagonists; therefore, the plant extract seems to exert its antidepressant effects through 5-HT _1A_ receptors [48]. Several years later, Liu et al. [49] determined that one of the active principles of this plant extract was the compound (−)-syringaresinol-4-O-β-D-apiofuranosyl-(1 → 2)-β-D-glucopyranoside (52, Fig. 6S, Supplementary Information), which increased the percentage of entries into and time spent on the open arms of the EPM while lowering the concentration of ACTH and corticosterone in plasma and decreasing the amount of neurotransmitters (DA, NA, 5-HT) and their metabolites in the cerebral cortex and hippocampus of treated rat brains. These results point to disease inhibition via the HPA axis [49]. _Albizia lebbek_ decreased the duration of immobility time in a dose-dependent manner in both the FST and TST in mice but exerted no effect on the locomotor activity of the mice [50].

Daily administration of _Allium cepa_ powder reduced the immobility time in the FST without changing the motor dysfunction. The authors concluded that onion’s antidepressant-like activity is independent of the HPA axis because plasma corticosterone levels were not affected [51]. Ten years later, Samad et al. [52] tested onion powder in mice with various protocols, including the EPM, LDA, FST, and MWM. They also examined the powder’s effects on brain lipid peroxidation, antioxidant enzymes, and AChE. They concluded that antioxidant enzymes have a relevant role in the attenuation of stress-induced anxiety and depression and that they also enhance cognitive function [52]. _Allium macrostemon_ was likewise studied with the FST and TST protocols; _in vitro_ tests with the born cells in the subgranular zone and the granule cell layer were also carried out and the expression levels of BDNF were examined by means of western blotting and immunohistochemistry. The results demonstrated that the immobility duration in both tests was reduced, whereas there were increases both in the number of cells and in the BDNF expression levels, which are associated with neurogenesis [53]. Chen et al. [54] also studied the antidepressant-like effect of this species but with a rat model of depression induced by exposure to chronic immobilization stress; the results were obtained through chromatographic methods. Differences were noted between the plasma lipid and acylcarnitine profiles of depressed rats and those in the control group, with most of the dysregulated metabolites returning to their normal values in the treated rats. These changes indicate that depression in rats is associated with several inflammatory conditions along with an incomplete β-oxidation of fatty acids [54]. The third species of _Amaryllidaceae_ to be studied was _Allium sativum_. In this case, researchers tested the effects of the essential oil after 28 consecutive days, with a reduction of the immobility time (FST) and a reversal of the decrease in the sucrose preference index induced by 5 wk of CUMS. The essential oil also decreased the frontal cortex turnover ratio of 5-HT and DA by increasing their levels but had no hippocampal effects. However, its chronic administration was shown to increase hippocampal BDNF, CREB, and Akt expression, most likely due to the modulation of monoamine neurotransmitters and the BDNF-related signaling pathway. The authors were unable to unequivocally establish the main active principle; when they tested garlic’s major organosulfur
component, diallyl disulfide, it showed less activity than the essential oil, which points to the presence of other active principles in garlic [55].

_Aloysia gratissima_ was tested by Zeni et al. [56] in mice. The anti-immobility effect caused by the TST was prevented by specific antagonists of the monoaminergic receptors, leading to the conclusion that the activity of the compound depends on the serotoninergic (5-HT1A and 5-HT2A/2C), noradrenergic (α1 and α2), and dopaminergic (D1 and D2) systems [56]. _Aloysia polystachya_ was tested in both the EPM and FST on female rats. The authors established that the monoterpene thujone and carvone, among others, may be potential active compounds, with a possible mechanism in which GABA could be implicated [57]. However, in a second study they cited flavonoids as the most likely active compounds [58]. Recently, the main chemical compound of the extracts was established as being acetoside [53, Fig. 6S, Supplementary Information], which might also be the active principle. This experiment involved examining the effect of caffeine on zebrafish, which produces an anxiogenic effect that can be reversed by the hydroalcoholic extract in the same way that fluoxetine does. The researchers thus concluded that _A. polystachya_ has anxiolytic and antidepressant-like activity, probably due to the presence of acetoside [59]. In the case of _Aloysia citriodora_, the authors proposed the implication of the GABAergic and serotonergic systems, which could mean that this plant may also function as an antidepressant-like drug in addition to its anxiolytic properties [60]. There are other studies on the plant’s CNS activity; however, the use of different extracts (polar and non-polar) hinders an accurate evaluation of the results in order to elucidate the activity of lemon verbena as an antidepressant-like plant [61].

When _Anacyclus pyrethrum_ was tested for antidepressant-like activity, it reduced the immobility caused by both the FST and TST, prompting the authors to hypothesize that the antidepressant-like effect could be due to its interaction with adrenergic and dopaminergic receptors, and through an increase in DA and NA levels in the brains of mice [62]. The main bioactive principle of _Andrographis paniculata_, andrographolide (23, Fig. 3S, Supplementary Information), which had previously been tested for multiple pharmacological properties, was recently evaluated as a potential antidepressant agent in mice. Andrographolide showed activity in both the FST and TST without influencing the locomotor activity of the test mice; it also exhibited significant antidepressant-like effects in the CUMS model and prevented decreases in hippocampal BDNF signaling and neurogenesis in mice, an effect that could be considered the antidepressant-like mechanism [63]. Using the FST, Ren et al. tested the effects of sarsasapogenin (6, Fig. 15, Supplementary Information) isolated from _Anemarrhena asphodeloides_ in mice. The compound affected the immobile response but did not modify the locomotor activity. It also increased NA and 5-HT levels in both the hypothalamus and the hippocampus. Moreover, sarsasapogenin inhibited MAO in the mouse brain. The authors therefore hypothesized that the antidepressant-like activity of sarsasapogenin involves the central monoaminergic neurotransmitter systems [64, 65].

Riparin III (80, Fig. 8S, Supplementary Information) from _Aniba riparia_ was studied as an antidepressant-like compound in different protocols. The compound decreased the immobility time in both the TST and FST, with no effects on the spontaneous motor activity in mice [66]. In a complementary study, these same authors established that the antidepressant-like effect is dependent on the compound’s interaction with the serotonergic, noradrenergic (α1 and α2), and dopaminergic (D2) receptors [67]. In addition, mice exposed to the corticosterone-induced chronic depression model and treated with riparin III showed increased BDNF protein levels in the hippocampus [68]. The compound likewise exhibited anxiolytic-like properties [69]. Riparin II (79) [70] and riparin I (78, Fig. 8S, Supplementary Information) [71] were also tested as potential antidepressant-like agents. The former was tested in rodents, with the results showing a significant decrease of immobility time in both the FST and TST. Pretreatment of test mice with receptor antagonists (α1, D1, D2, and 5-HT1A), an inhibitor of 5-HT synthesis, and a serotonin receptor antagonist completely blocked the anti-immobility effects elicited by riparin II in the FST. These results indicate that the antidepressant-like activity of riparin II is dependent on its interaction with the noradrenergic, dopaminergic, and serotonergic systems [70]. When riparin I was tested using the FST and TST, it also decreased the immobility time. Pretreatment with monoamine antagonists likewise demonstrated the implication of these systems in the compound’s effects [71].

Martínez-Vázquez et al. [72] studied an alkaloid-enriched extract from _Annona cherimolia_ in mice, using the FST for evaluating the compound’s activity as well as different agonist and antagonist effects of monoamines. The results gave a positive result, with the mechanism being attributed to an increase in monoamine turnover. The alkaloids in the extracts were identified as anonaine (63), liroliodene (64), nornuciferine (65), and 1,2-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzoquinoline-3,8,9,10-tetraol (66) (see Fig. 7S, Supplementary Information) [72]. _Annona coriacea_ was also evaluated, as well as caffeic acid (48, Fig. 6S, Supplementary Information), the major phenolic present in the extract. The results indicated that both samples have antidepressant-like effects as well as anxiolytic properties, both involving the GABAergic and monoaminergic systems [73]. _Annona vepetrum_’s essential oil was tested in a protocol similar to that used for _A. coriacea_ with similar results, but in this case, the antidepressant-like effect was related to its action on serotonergic receptors whereas its anxiolytic properties were associated with the GABAergic system [74].

_Apocynum venetum_, used in traditional Chinese medicine [75], was studied by Butterweck et al. [76] as a potential antidepressant-like agent in rats. The researchers speculated that the effect might be related to the major flavonoids present in the extract, hyperoside (37) and isoquercitrin (38, Fig. 15, Supplementary Information) [76]. They also compared the short-term (2 wk) and long-term (8 wk) effects of this extract with those of imipramine, detecting marked changes in DA and NA levels in the rat hypothalamus, striatum, and hippocampus after 8 wk; 5-HT levels were not affected. They also established the relationship between decreased NA levels and presynaptic α2-receptors, whereas there was no effect on the β-adrenergic receptors [77]. These results were corroborated by Zheng et al. [78], who studied the antidepressant-like effect and monoaminergic mechanism of a flavonoid-enriched extract of this plant. The results were attributed to
increased levels of NA and DA, together with their respective metabolites, in the mouse hippocampus, which were dependent on the interaction of the extract with D1 and D2 receptors [78]. Previously, some authors had suggested that the flavonoid hyperoside could be the principal antidepressant agent and proposed a possible mechanism of action involving a heightened expression of BDNF and CREB through the signal pathway AC-cAMP-CREB [79]. Additional studies with the same extract in rats using the CUMS model showed reduced serum corticosterone and ACTH levels. The extract also increased the activities and gene expression of antioxidant enzymes such as SOD, catalase, and glutathione peroxidase, while decreasing ROS generation levels and lipid peroxidation in the rat hippocampus. Moreover, the extract suppressed the apoptosis of hippocampus cells by modulating the Bcl-2/Bax pathways and improved hippocampal BDNF expression. The researchers concluded that the extract exerted antidepressant-like effects through prevention of oxidative stress, the inhibition of hippocampal neuronal apoptosis, and the upregulation of hippocampal BDNF levels [80]. In a similar study, Wu et al. [81] demonstrated that the extract improved depressive behavior in CUMS rats because it reversed the increased apoptosis of hippocampus and cortical neurons and increased Bcl-2, BDNF, and CREB protein expression while simultaneously decreasing Bax, cytochrome c, and caspase family protein expression. These findings indicate that A. venetum exerts its antidepressant-like activity mainly through the suppression of neuronal apoptosis.

_Areca catechu_ is the fourth most widely used psychoactive substance in the world after caffeine, nicotine, and alcohol [82]. Previous reports have shown that this nut exerts antidepressant-like effects in mice and rats in both the FST and TST while also decreasing the levels of MAO in rat brain homogenates. Areca nut has also been shown to have antidepressant-like effects in mice and rats; in this case, the activity was associated with the regulation of DA and 5-HT levels through MAO inhibition [83]. It has also been tested using behavioral and biochemical tests in rats and showed activity in both the acute and sub-chronic FST, with the saponins being the most likely active compounds due to the significant elevation of 5-HT and NA levels compared to the controls [82]. _Artemisia absinthium_ reduced the immobility period in both the FST and TST in a dose-dependent manner. In this case, the activity was associated with the compound’s antioxidant properties, which come from its high content in flavonoids and other phenolics [82]. _Asparagus racemosus_ decreased immobility in the FST and increased the avoidance response in the LHT, which is indicative of antidepressant-like activity. The authors concluded that this activity could be mediated through the serotonergic and the noradrenergic systems, as well as an increase in antidepressant defenses [84, 85]. Moreover, _A. racemosus_ is a nonselective competitive inhibitor for both AChE and MAO enzymes and thus may produce some interactions with other drugs and food [86].

_Bacopa monnieri_ is used as a dietary antioxidant and has been described as a protector of the brain against oxidative damage and age-related cognitive decline [87–89]. Sairam et al. [90] described the effect of a standardized extract (38% of bacoside A, 7, Fig. 25, Supplementary Information) as antidepressant-like in FST and LHT models of depression in rats, but no mechanisms were proposed [90]. Bhattacharya et al. [91] demonstrated its antioxidant properties while also finding evidence of reduced oxidative stress in the aging brain, which could be hypothesized as a mechanism for improving cognition [89]. _Basella alba_ showed similar activity in both the FST and TST, most likely due to the main compounds present in the extract, which include alkaloids, tannins, and flavonoids, but no mechanism was proposed [92]. In the case of _Benincasa hispida_, the activity (assayed with the FST) is due to the inhibition of MAO-A; an interaction with the dopaminergic, α1-adrenergic, serotonergic, and GABAergic systems was implicated in the mechanism [93]. _Boophone disticha_ was also tested with the FST and TST and showed functional inhibition of SERT, NAT, and DAT. Various studies with Amaryllidaceae alkaloids, including those present in this plant, showed activity with regard to SERT, while the alkaloids buphanidine (76) and buphanamine (77, Fig. 75, Supplementary Information) were shown to exhibit selective 5-HT reuptake inhibition, leading the authors to establish alkaloids as the active compounds in this plant [41, 94]. _Bupleurum falcatum_ reduced the total duration of immobility in mice in the TST with no modification observed in the OFT. The activity was dose-dependent and involved the serotonergic and noradrenergic systems [95]. In addition, it significantly reduced depression-like symptoms following repeated restraint stress through hypothalamic CRF modulation and noradrenergic system regulation in the locus coeruleus of treated rats [96].

_Camellia sinensis_ leaves are commercially available in different forms, differing mostly in the degree of fermentation, which has an effect on their antioxidant properties [97]. Several studies have established the relationship between a higher consumption of green tea and a lower prevalence of depression [98]. To confirm these properties, Zhu et al. [99] used different mouse models of depression (FST and TST) for testing green tea polyphenols and their mechanisms of action as potential antidepressant agents. Green tea polyphenols were found to reduce immobility in both tests. They also reduced serum corticosterone and ACTH levels, but did not modify the locomotor activity in the OFT. This led the researchers to conclude that the polyphenols in green tea exert their antidepressant-like effects in mice through the inhibition of the HPA axis [99]. In a complementary study, Liu et al. [100] investigated the antidepressant-like effects of tea polyphenols using the mouse model of CUMS-induced depression and found that the activity was exerted through both monoaminergic pathways (5-HT and NA) and antioxidant defenses [100]. Similar results were obtained by Di Lorenzo et al. [101], who used both green tea and GABA green tea (special green tea with a high GABA content) in a mouse model of post-stroke depression. Both teas showed a significant effect on the modulation of depressive symptoms, restoring normal behavior and improving the antioxidant endogenous defenses through the reduction of oxidative stress [101]. GABA green tea was also studied by Teng et al. [102], who observed that the GABA present in green tea has a healthy effect on the prevention and alleviation of depression by modulating GABAergic neurotransmission in the mouse cerebral cortex by up-regulating the expression of the GABA_A receptor α1 subunit [102].

_Concanavalin Br is a lectin with mannose/glucose affinity isolated from_ Canavalia brasiliensis _seeds._ When this compound was tested in a mouse FST model, it elicited an anti-immobility effect.
that could be prevented by pretreating the test mice with different receptor antagonists (5-HT_{1A/B}, 5-HT_{1A}, 5-HT_{2A/2C}, D2, and α2) but not with the D1 or α1 receptor antagonists. This indicates that the antidepressant-like effect of this lectin elicited in this protocol is due to its interaction with the serotoninergic, noradrenergic, and dopaminergic systems. Considering the presence of lectins in the brain and based on these results, the elucidation of a possible role of endogenous lectins in the modulation of CNS system function is of great interest [103]. The same research group [104, 105] thus went on to study the role of concanavalin Br in the brain along with the role of endogenous lectins in the modulation of CNS function. Because many receptors, ion channels, and transporters making up the CNS are glycoproteins, where the glycan chains are modulator elements and lectins are proteins, these recognize and bind carbohydrate complexes. The antidepressant and neuroprotective effects of concanavalin Br may thus be dependent on carbohydrate interaction. Rieger et al. [104] demonstrated that this lectin improves BDNF expression, probably through a mechanism dependent on CREB activation mediated by PKA, ERK1, and Akt. In addition, this lectin inhibited the NMDA receptor and reduced NO and cGMP synthesis [105], which could justify in part the antidepressant-like effect of concanavalin Br in the FST. Zhao et al. [106] found that the ethanolic extract of the flowers of *Carthamus tinctorius* inhibited 5-HT uptake in Chinese hamster ovary cells. Following an activity-guided isolation, these researchers identified 3α,6α-(Z)-6α,7α,8α-tri-p-coumaroylsperrmidine (81, Fig. 85, Supplementary Information) as the active principle. After more testing, this compound was found to be a novel 5-HT transporter inhibitor, with IC_{50} values of 0.74 μM (S6 cells) and 1.07 μM (synaptosomes), and with a reversible competitive property for the inhibition of 5-HT-uptake [106]. Oazi et al. [107] studied the petal extract with similar results in an FST [107] while Abbasi-Maleki et al. [108] studied the flower extract in a TST model and described the involvement of both dopaminergic (D1 and D2) and serotonergic (5-HT_{1A} and 5-HT_{2A}) receptors. They postulated a relevant role for N-hexadecanoic acid as the major compound found in the extract (about 20%) [108]. *Casimiroa edulis* reduced the immobility time with respect to the controls, increasing the climbing behavior in a similar way as the selective 5-HT reuptake inhibitor fluoxetine; however, the authors did not cite any active principles [109]. Han et al. [110] isolated 7 flavonoids from a methanol extract of *Clitoria ternatea* has been used in Ayurvedic medicine for centuries to treat various nervous system diseases, including as an antidepressant [120], but an early study concluded that the alcoholic extract only acts at high doses [121]. Some year later, Jain et al. [122] observed that the extract decreased the duration of immobility in the TST. It also showed a tendency to reduce the intensity of behavior mediated by 5-HT and ACh whereas its effect on behavior mediated by DA and NA was not significant [122]. Malik et al. [123] further corroborated these findings and evaluated the activity in the TST in mice. In another study, the immobility time of rats was also reduced in a dose-dependent manner in both the FST and TST, leading the authors to hypothesize that the effects may be due to the presence of flavonoids and that the mechanism could involve an interaction with the GABA_{A} receptors [124]. Dhingra and Valecha [125] assayed different extracts of *Citrus prostratus*, but only the chloroform fraction was found to significantly reduce the immobility time in both the FST and TST by interacting with the adrenergic, dopaminergic, and serotonergic systems. However, the methanolic extract showed antidepressant-like effects in the SPT, FST, and CUMS. Moreover, the extract reduced the increased levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, and the liver biomarkers ALT and AST in CUMS-exposed rats. Furthermore, the extract restored the NA and 5-HT levels in the hippocampus as well as in the PFC of CUMS-exposed rats. The authors thus concluded that *C. prostratus* exerted its antidepressant-like effect through its anti-inflammatory properties, restoring liver biomarkers and monoaminergic responses in the stressed rats [126].
of flavonoids, cyanidins, and anthraquinones [127–131]. Saffron has been used and assessed as a medicinal agent, and different properties have been described for both saffron and its principles [127, 132–138]. However, the principal interest in saffron could be due to its anticonvulsant, anti-anxiety, and hypnotic properties [139, 140]. In addition, antioxidant properties have been attributed to saffron and its various compounds [141, 142], which may partly justify its neuroprotective effects. Several recent studies have demonstrated that saffron not only inhibits reuptake of monoamines (DA, NA, 5-HT), but that it also exhibits both NMDA receptor antagonism and GABA<sub>A</sub> agonism, which seem to be responsible for its antidepressant-like and anxiolytic effects demonstrated in animal models (EPM and OFT) [143–145]. Two extracts of <i>Cucurbita pepo</i> were studied in an FST model in rats and found to decrease immobility time, with the antioxidant properties of the aqueous extract being responsible for this effect [146]. The total furocoumarin extract of <i>Cullen corylofolium</i> was likewise tested with the FST and was found to reduce the immobility time and inhibit both MAO-A and MAO-B, with a more potent effect on the latter. The extract also blocked plasma-elevated cortisol levels and decreased liver SOD activity and MDA levels. The authors concluded that the antidepressant-like effects of furocoumarin extract are mediated by MAO activity, HPA axis action, and oxidative stress [147]. A similar study was performed by Xu et al. [148] and Yi et al. [149], but in these experiments, the authors concentrated on psoralen (49, Fig. 6S, Supplementary Information), the major compound found in the furanocoumarins [148] and psoraldin (51, Fig. 6S, Supplementary Information) [149]. Psoralen reversed FST-induced alterations in 5-HT levels in the frontal cortex and hippocampus in mice while attenuating FST-induced elevations in serum CRF and corticosterone [148]. Not only did psoraladin affect 5-HT, CRF, and corticosterone levels, but it also changed DA levels in the striatum of mice exposed to FST while elevating ACTH in serum [149]. These results point to an implication of both the monoamine neurotransmitter and the HPA axis systems [148, 149].

Turmeric (<i>Curcuma longa</i>) is used as a condiment and flavor corrector, although its use in phytotherapy is also well-established. The European Pharmacopoeia recognizes the entire rhizome as a phytherapeutic agent [150–154]. The species <i>C. aromatica</i> and <i>C. zanthorrhiza</i> are also used for the same purposes [150, 151, 155–158]. Of its various pharmacological properties, the anti-inflammatory [155] and neuroprotective [156, 157] properties are the most remarkable. Different researchers have focused their efforts on demonstrating the properties of curcumin (57, Fig. 6S, Supplementary Information), the main active component, and its potential as a therapeutic agent, especially in CNS pathologies. Consequently, interest in this compound as a possible antidepressant has grown in recent years, with studies focusing on its antidepressant activity in relation to its anti-inflammatory properties. Indeed, both the anti-inflammatory and antioxidant properties of curcumin have been demonstrated in various studies [12, 158, 159] using different experimental protocols; this has favored the jump to its clinical use. Among the antidepressant effects of curcumin observed in animal models, the most notable are its action on the neurotransmitters involved in depression, its modification of the response of the HPA axis, and its reduction of oxidative stress and mitochondrial damage [160] due to its anti-inflammatory and antioxidant properties. More than 40 studies have been conducted in animals using the aforementioned protocols, including the FST or TST, although other more specific techniques have also been used, such as sleep deprivation, immobilization stress, and cold stress, all as models of chronic stress. Surgical procedures including bilateral olfactory bulbectomy and ligation of sciatic nerves have also been employed [6]. In all cases, the findings have indicated a possible antidepressant effect. For example, it was demonstrated that the administration of curcumin to rats and mice improves the study parameters, both in acute and chronic depression models, with similar effects to those obtained with fluoxetine and imipramine [6, 160, 161]. The results also demonstrated that the antidepressant mechanism of curcumin involves both the serotonergic system [162] and the AC-cAMP pathway [163]. Curcumin has also been shown to improve the anti-immobility effect of subliminal doses of various antidepressant drugs such as fluoxetine, venlafaxine, or bupropion [164], while the combination of curcumin with piperine (a bioavailability enhancer) significantly increased the anti-mobility effects, the potentiation of the neurotransmitters 5-HT and DA, and the inhibitory effects of MAO-A with respect to curcumin administered alone [165]. Other studies established the effect of curcumin in rats with bilateral olfactory bulbectomy, which causes behavioral changes that lead to characteristics similar to those observed in patients with depression. Bulbectomy causes important dysfunction in the cortico-hippocampal-amygdaledial circuit similar to that observed in depressed people [166]; however, researchers found that the administration of curcumin modifies the changes provoked by bulbectomy as effectively as antidepressants, reducing the immobility time and reversing the behavioral abnormalities induced by the procedure [167]. Curcumin also attenuated the depletion of monoamines and the reserpine-induced increase of oxidative stress [168] along with the behavioral changes induced by corticosterone [169]. In addition, curcumin was shown to revert or protect rat hippocampal neurons from damage in response to chronic stress via positive regulation of 5-HT<sub>1A</sub> and BDNF receptors, 2 molecules involved in the neurogenesis of the hippocampus [170]. Ceremuga et al. [171] studied the anxiolytic and antidepressant-like effects of curcumin in various selective tests and concluded that curcumin’s effects were not due to its interaction with the benzodiazepine site of the GABA<sub>A</sub> receptor. This means that the observed effects are likely due to the modulation of other subunits on the GABA<sub>A</sub> receptor or even interactions with other CNS neurotransmitter systems, thereby confirming the mechanisms previously cited for curcumin [171]. Table 1 contains a concise summary of the main results obtained in vivo, with reference to the possible mode of action and the mediators involved in the mechanism of action of curcumin as an antidepressant. The total glycoside-fraction of <i>Cynanchum auriculatum</i> was also tested with the FST, TST, and LAT. In addition, the authors tested for the inhibition of 5-HT reuptake in rat brain synaptosomes to conclude that the antidepressant-like effects are due to the inhibitory effect on serotonin reuptake [172].

<i>Eleutherococcus senticosus</i> is used with similar indications to those of <i>Panax ginseng</i>, although in the latter, other organs such
activity was attributed to the serotoninergic (5-HT2A/2C) and noradrenergic (α1/2) receptors; the dopaminergic system was not involved [179].

**Table 1** Some relevant in vivo studies on the antidepressant-like activity of curcumin.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Effect</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–80 mg/kg, i. p., mice</td>
<td>Reduced the period of immobility and increased levels of 5-HT and DA (at higher doses) and inhibited both MAO-A and MAO-B</td>
<td>[164]</td>
</tr>
<tr>
<td>20 and 40 mg/kg, i. p., 21 days with piperine (2.5 mg/kg, i. p., 21 days), rats</td>
<td>Increased the anti-mobility effect, potentiation of the neurotransmitters 5-HT and DA, and the inhibitory effects of MAO-A with respect to curcumin administered alone</td>
<td>[165]</td>
</tr>
<tr>
<td>1.25–10.0 mg/kg for 14 days, rats</td>
<td>Reduced the immobility time and reversed the behavioral abnormalities induced by said procedure</td>
<td>[167]</td>
</tr>
<tr>
<td>100–300 mg/kg, i. p., rats</td>
<td>Attenuates depletion of monoamines and the increase of oxidative stress with reserpine (1 mg/kg, s. c., 3 days)</td>
<td>[168]</td>
</tr>
<tr>
<td>20 mg/kg, p. o. and corticosterone (40 mg/kg, s. c.) for 3 weeks, rats</td>
<td>Reduce the alteration of the behavior of the rats after an injection of corticosterone. There was a 46% increase in sucrose consumption and 57% reduction in immobility time versus negative control (only corticosterone).</td>
<td>[169]</td>
</tr>
<tr>
<td>10 and 20 mg/kg, p. o., rats</td>
<td>Revert or protect hippocampal neurons from increased damage via positive regulation of 5-HT1A and BDNF receptors</td>
<td>[170]</td>
</tr>
</tbody>
</table>

i. p., intraperitoneal; p. o., per os (orally); s. c., subcutaneous

as leaves are also employed [173], including for the treatment of mental and emotional problems, as well as an antistress agent [174]. This has prompted several research groups to investigate its efficacy as an antidepressant in animals, but no studies in humans have been reported. In this context, Jin et al. studied the antidepressant-like activity at very high doses using FST and TST protocols. The higher dose elevated the levels of 5-HT, NA, and DA in the whole mouse brain. Moreover, the extract upregulated the level of CREB protein at both doses, leading the authors to hypothesize that the antidepressant effects of *E. senticosus* are mediated by the central monoaminergic neurotransmitter system and CREB protein expression [174]. In a complementary study, Wu et al. [175] demonstrated the protective effects of *E. senticosus* on corticosterone-induced neurotoxicity (PC12 cells) as an in vitro model of depression. They observed that the extract increased cell viability, decreased lactate dehydrogenase release, suppressed the apoptosis of PC12 cells, attenuated intracellular Ca2+ overloading, and upregulated BDNF mRNA levels and CREB protein expression in comparison with the control group. One year later, Gaire and Lim [176] studied the antidepressant effects of *E. senticosus* in rats (TST and FST) and evaluated the serum corticosterone levels. They noted that at the higher dose, the extract ameliorated depressive behaviors and restored HPA activity [176]. Icarin (44, Fig. 55, Supplementary Information), a prenyl-flavonoid glycoside isolated from *Epimedium brevicornu*, was tested in a CUMS model of depression in rats. Administration of icariin reversed the CUMS-induced sucrose intake reduction and CRF elevation, which affected the HPA axis functions but not the hypothalamus-pituitary-thyroid (HPT) axis [177]. Two species of *Eugenia, E. brasiliensis* and *E. uniflora*, were tested both for their antidepressant-like effects and to assess the implication of the monoaminergic systems in the mechanism of action. In the case of *E. brasiliensis*, the effect in the TST was mediated by the serotoninergic (5-HT1A and 5-HT2F), noradrenergic (α1), and dopaminergic (D2 and D3) systems [178], whereas in the case of *E. uniflora*, the activity was attributed to the serotoninergic (5-HT2A/2C) and noradrenergic (α1/2) receptors; the dopaminergic system was not involved [179].

*Gastrodia elata* has previously been studied as an antidepressant in different tests in which the serotoninergic and dopaminergic systems were implicated [180, 181]. In addition, when it was tested in the CSDS model, it ameliorated depression-like behaviors and stress-induced elevations of corticosterone. It also increased the expression of BDNF and promoted the hippocampal protein phosphorylation ratio of CREB and Akt as a possible mechanism of action [182], whereas in the CUMS protocol this extract restored the cerebral turnover rates of DA and 5-HT and decreased serum corticosterone levels [183]. *Gentiana acaulis* and its major compound, gentiacauline, inhibited MAO-A activity in a crude brain mitochondrial fraction of mice treated with the extract [184]. The standardized extract (Ginkgolone-24) of *Ginkgo biloba* reduced the immobility time in both the FST and TST, prompting researchers to assign its antidepressant-like activity to flavonoid-glycosides; however, other compounds were also implicated, including ginkgolides and bilobalide. The most likely mechanism involves the extract’s effects on monoamines and MAPKs in the brain [185]. In the case of the EGb761 standardized extract, Rojas et al. [186] suggested that the antidepressant-like effect may be partly due to its observed neuroprotective effects through its antioxidant properties [186]. Recently, Zhang et al. [187] described the compound’s antidepressant-like activities and the improved cardiac function in mice with heart failure (SPT and OFT), with the compound reducing levels of TNF-α, IL-1β, and 5-HT in the hippocampus, blocking the release of 5-HT in peripheral blood and triggering HIF-1-induced anti-apoptotic pathways [187]. *Glycyrrhiza glabra* (liquorice) reduced the immobility times of mice in both the FST and TST, with various monoamine receptor antagonists (D2 and α1) reducing the effect, indicating that the extract’s antidepressant-like effects are due to an increase of DA and NA (but not of 5-HT) activity in the brain [188]. In the case of *G. ura- lensis*, similar effects were observed in the same tests when the isolated compounds liquiritin (40) and isoliquiritin (41, Fig. 55, Supplementary Information) were used, but in these experi-
ments, the mechanism of action for both compounds was attributed to the increase of 5-HT and NA in the mouse hippocampus, hypothalamus, and cortex, with no effect on DA [189].

_Handroanthus impetiginosus_ was studied for its antidepressant-like effect (FST, TST, OFT), with the anti-immobility effect being related to the serotonergic (5-HT1A), adrenergic (α1, α2, and β), and dopaminergic (D1 and D2) systems [190] as it increased not only both CREB and ERK1 phosphorylation but also BDNF signaling pathways in olfactory bulbectomized rats [191]. Moreover, it reduced NO levels in the cerebral cortex, an effect that is dependent on a blockade of NMDA receptor activation and inhibition of NO-cGMP synthesis [192]. _Hedyosmum brasiliense_ also exerted an antidepressant-like effect (FST and TST), as did its isolated sesquiterpenoid, podoandin (20, Fig. 35, Supplementary Information). The activity was reported to be dependent on the serotonergic, noradrenergic, and dopaminergic systems but not on the GABAergic, opioid and oxidonitrergic systems [193]. _Hemerocallis citrina_ reduced the immobility time in both the FST and TST models for depression in mice with no concomitant changes in locomotor activity observed in the OFT. These results were found to be dependent on the serotonergic (5-HT1A and 5-HT2A), noradrenergic (α1, α2, and β), and dopaminergic (D2) systems, as well as on the elevation of 5-HT, NA, and DA levels in the mouse brain [194]. Moreover, the extract reversed the aforementioned changes and upregulated the BDNF and TrkB receptor protein expression in both the frontal cortex and hippocampus [195] while reversing the decreased sucore preference in the SPT and inhibiting IL-1β, IL-6, and TNF-α expression [196]. When the potential neuropharmacological components of a standardized mixture of its principal flavonoids rutin (45) and hesperidin (46) (Fig. 55, Supplementary Information) were tested, the activity was attributed to the serotonergic and dopaminergic systems [197]. Xu et al. [198] tested the total phenol fraction of _H. citrina_ using a CUMS model and described a potential mechanism mediated by regulation of neurotransmitters and BDNF levels in the brain and alleviation of both the corticosterone levels and oxidative stress [198]. The flavonoid hesperidin has also been shown to exert an antidepressant-like effect mediated in an ERK-dependent manner [199]. _Hibiscus rosasinensis_ decreased the immobility time (TST and FST) and attenuated the duration of immobility induced by D2 and α1 antagonists, and acted as an 5-HT inhibitor synthesis in both tests. These results indicate the implication of the dopaminergic, noradrenergic, and serotonergic systems [200]. In the case of _Hippeastrum vittatum_, the alkaloid montanine (73, Fig. 75, Supplementary Information), isolated from fresh bulbs, was found to increase the time spent struggling in the FST model, but no mechanism was proposed [201]. _Hordeum vulgare_ showed an antidepressant-like effect in the FST, reducing both the duration of immobility and the expression of mRNA for nerve growth factor in the hippocampus in a dose-dependent manner, which could also be the mechanism for its antidepressant activities [202]. Both the CO2 extract and the α-acid-enriched fraction of _Humulus lupulus_ reduced immobility time during the behavioral despair test, but neither of them affected the locomotor activity in the OFT or exerted an anxiolytic effect [203].

The genus _Hypericum_ includes over 500 species, which often leads to confusion for some authors, since different species are used around the world. The species _Hypericum perforatum_ is known as St. John’s wort, and its flowering tops have traditionally been used in Europe as a first-line treatment of major depressive disorder [12, 204]. There are 2 main groups of principles, naphthodianthrones (hypericin 55 and similar) and phloroglucinols (hyperforin 56 and others) (Fig. 65, Supplementary Information), but other constituents are also relevant. The presence of pyrrolizidines is not natural in the plant, although they may appear during the harvesting process [205]. Several _in vitro_ studies have established that St. John’s wort could be an inhibitor of MAO-A and MAO-B activity while also inhibiting the neuronal reuptake of serotonin, dopamine, and noradrenaline; however, it also has a significant affinity for adenosine, GABA_A, GABA_B, and glutamate receptors. Other studies have demonstrated a relationship between the activity of St. John’s wort extract and the downregulation of β-adrenergic receptors with a concomitant upregulation of 5-HT2 receptors. Recent research has also established the implication of several compounds (most likely hypericin, hyperforin, and several flavonoids) in the regulation of genes that control HPA axis function. With regard to the antidepressant effects of St. John’s wort extract, many of the pharmacological activities appear to be attributable to hypericin, hyperforin, and several flavonoids [206]. In this last case, one study has shown that the absence of rutin reduced the antidepressant activity of St. John’s wort, and that hyperforin was the only plant compound present in the brains of rodents after oral administration of the alcoholic extracts, unlike hypericins and flavonoids, which were not present [207]. Bukhari and Dar [208] tested a standardized extract of _H. perforatum_ using the FST as an animal model of depression and found that the antidepressant-like properties were related to selective 5-HT reuptake inhibitors. Recently, Zirak et al. [209] reviewed this species and established that _H. perforatum_ and its principal compounds, hypericin and hyperforin, possess antidepressant properties similar to those of tricyclic antidepressants and SSRI and that their mechanism is due to inhibition of MAO-A, modulation of the concentrations of DA, 5-HT, and NA in the brain and peripheral tissues, inhibition of synaptosomal reuptake of amines, inhibition of monoamine transporters, and upregulation of 5-HT1A and 5-HT2A receptors. Apparently, hypericin is the main active principle from the extract [209]. Other species of _Hypericum_ have also been studied as potential antidepressant-like agents, including _H. canariense_ [210], _H. caprifoliatum_ [211–217], _H. glandulosum_ [210, 211], _H. grandifolium_ [211], _H. perfoliatum_ [218, 219], _H. polyanthemum_ [220], and _H. reflexum_ [211]. All were studied in similar protocols, but _H. caprifoliatum_ was the most extensively researched, with both the extract and the phloroglucinol fraction evaluated in an FST model. The activity was associated with an increase in monoaminergic transmission due to the inhibition of monoamine uptake [212], along with the inhibition of Na⁺ influx, which increases hippocampal and cortical Na⁺-K⁺-ATPase activities [213] by the phloroglucinol compounds. The lipophilic extract was also found to prevent stress-induced corticosterone increases in the mouse frontal cortex but not in plasma, exerting an anxiolytic effect mediated indirectly by the opioid system [214]. It was also shown to reduce immobility time and the FST-induced increase of serum and cortical corticosterone levels while modifying the HPA axis reactivity to stress [215]. Other studies have focused
on the flavonoid hyperoside, the antidepressant-like effect of which in rats was prevented by sulpiride, a D₂ antagonist, thus implicating the dopaminergic system [216]. But recently, Stolz et al. [217] tested the effect of the dimeric phloroglucinol uliginosin B (54, Fig. 6S, Supplementary Information) using various protocols and observed that uliginosin B inhibited monoamine reuptake, activated DA receptors, and indirectly stimulated the opioid system [217].

Macranthol (60, Fig. 6S, Supplementary Information) from Illicium dunnianum was tested in the FST, TST, and CUMS models, attenuating the reduction of serotoninergic neurotransmission in the frontal cortex and hippocampus regions of the brain and ameliorating the chronic but not acute, treatment-enhanced BDNF expression [221]. This antidepressant-like action was associated with BDNF-TrkB and downstream activation of the PI3K/Akt-Bcl-2/caspase-3 signaling pathway [222]. In addition, this lignan decreased the levels of elevated pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in serum and the PFC, indicating that the antidepressant-like properties may be mediated by the suppression of microglia-related neuro-inflammation in the PFC [223]. The compound 1,3,7-trihydroxy-2-(3-methylbut-2-enyl)-xanthone (62, Fig. 6S, Supplementary Information) from Kielmeyera coriacea acts as an antagonist of 5-HT₃A autoreceptors in the intra-median raphe nucleus while increasing 5-HT availability in projection regions [224]. Lafaenosa pacari reduced immobility time in antidepressant-like tests (FST, TST, and OFT) in mice without affecting motor activity; however, no mechanism or active compounds were cited [225]. In a second study, it exerted the effect by acting on the serotoninergic and catecholaminergic systems and increased hippocampal BDNF levels without affecting MAO activity, with the phytochemical analysis indicating the presence of saponins, tannins, steroids, and triterpenes [226].

Different species of Lavandula and their essential oils have been reviewed by Cavanagh and Wilkinson [227], who noted that aromatherapy with these oils could be effective due to both the psychological and the physiological effects of the inhaled volatile compounds because of the participation of both the amygdala and hippocampus. Although the mechanism is unknown, some authors have suggested that the essential oil of lavender (Lavandula angustifolia) may have a similar action to that of benzodiazepines, enhancing the effects of GABA in the amygdala. Other authors have cited the effect of linalool (18, Fig. 35, Supplementary Information), which serves as an ACh release inhibitor and alters ion channel function at the neuromuscular level [227]. Hritcu et al. [228] used the EPM and FST to evaluate the effects of the essential oils of lavender on neurological capacity in a scopolamine-induced dementia model in rats, demonstrating that these essential oils exert antidepressant activity. In a similar study, the hydroalcoholic extract ameliorated scopolamine-induced memory impairment and depression-like behavior in a dose-dependent manner [229]. Lavender oil and linalool also modulate the neuroendocrine system by interfering with activation-induced cryptopath breakdown and indoleamine 2,3-dioxygenase activity [230]. López et al. [231] established that lavender essential oil exerts its effects by modulating the NMDA receptor. Caputo et al. [232] analyzed both the essential oil and linalool, demonstrating that both compounds reversed social aversion behaviors, while linalool also inhibited the expression of phosphorylated-ERK and kinase A, which are involved in the transmission of nerve signals [232]. The oral administration of lavender essential oil attenuated nerve injury-induced neuropathic pain symptoms in mice while simultaneously exerting an antidepressant-like activity through the inhibition of spinal ERK and JNK phosphorylation, along with the reduction of iNOS expression [233]. Lepidium meyenii (Macca) has been used to treat various maladies, including depression. It was tested in the CUMS model of depression in mice and was found to decrease immobility time in the TST; it also reduced corticosterone levels in serum. In addition, DA and NA levels increased and ROS were inhibited in the mouse brain tissue [234]; however, MAO-A was not inhibited [235]. Lycium barbarum’s (wolfberry) antidepressant-like effect is due to the enhancement of synaptic plasticity but not hippocampal neurogenesis [236].

Marsilea minuta reduced immobility in the FST and TST in rodents, with the activity due to the downregulation of 5-HT₂A receptors in the frontal cortex [237]. Melissa officinalis is also used as an antidepressant [238], with its extracts and essential oil showing antidepressant-like effects in mice and rats [239–241]. In 2015, Lin et al. [242] tested rosmarinic acid (58, Fig. 6S, Supplementary Information), and found that both extract and rosmarinic acid modulated serotoninergic neurotransmission and down-regulated the turnover of 5-HT in the FST model. Mimosa pudica reduced immobility time in both the FST and TST, but exhibited no effects in the OFT (locomotor activity) and increased DA and NA levels in the brain. In addition, the extract showed anti-anxiety and memory enhancing activities [243]. In the case of Mitragyna speciosa, the major alkaloid (mitragynine 67, Fig. 15, Supplementary Information) was tested and shown to reduce the immobility time of mice in both the FST and TST, with no concomitant effect on locomotor activities. The alkaloid also reduced the release of corticosterone in mice. The authors hypothesized that mitragynine’s antidepressant-like effects are most likely due to its interaction with the neuroendocrine HPA axis systems [244]. Monomorcha charantia also reduced the duration of immobility in the FST and TST; in this case, the antidepressant-like effect was found to be dependent on the monoamine receptors (5-HT₂, α₁, α₂, and D₂), but the muscarinic cholinergic systems and benzodiazepine-type receptor also seem to be implicated in the plant’s anxiolytic activity [245].

Morinda officinalis has antidepressant and anti-inflammatory activities [246]. Zhang et al. [247] studied its effects in an FST animal model of depression, as well as in a behavioral screening known to be both selective and sensitive to antidepressant drugs, namely the DRL 72-s schedule. The plant extract exerted effects similar to those of the antidepressant drug desipramine in rats in the DRL 72-s test, reducing the response rate and efficiency ratio and increasing the reinforcement rate. In the FST, the extract also elicited a significant reduction in the duration of immobility, as did the reference drug [247]. Other research has focused on the inulin-type oligosaccharides MW-97 (1 glucose and 3 to 6 fructose) and P₅ (6 units, 1 glucose and 5 fructose) obtained from this plant, finding that they both increased 5-HT levels in the brains of reserpinized mice while normalizing the hyperactive state of the HPA axis induced by chronic stress in mice or rats [248]. In a subsequent study, the same authors demonstrated that P₅ and de-
sipramine antagonize the apoptosis induced by corticosterone in PC12 cells, which may be one of the cellular mechanisms behind their antidepressant effects. In addition, MW-97 increased both the 5-HT levels and the activity of the Gs protein-AC-CAMP pathway, with both leading to an increase in the neurotrophic factors. This hypothesis explains why MW-97 increases the activity of AC in vivo, while having no effect in vitro. This inulin-type hexasaccharide (P6, but referred to as IHS in this paper) decreased intracellular Ca2+ overloading, thereby upregulating nerve growth factor mRNA expression in corticosterone-treated PC12 cells. This cytoprotective and neuroprotective action may be part of the mechanism behind its antidepressant effects [249,250]. Xu et al. [251] described the positive effects of a mixture of oligosaccharides from M. officinalis on chronic, unpredictable stress-induced depression-like behavior in the SPT and FST. Indeed, the mixture attenuated chronic, unpredictable stress-induced abnormalities in the BDNF-GSK-3β-β-catenin pathway and ameliorated synaptic protein deficits in the median–but not the orbitofrontal–PFC. However, the phosphoinositide-3 kinase inhibitor LY294002 reversed the antidepressant-like effects of these oligosaccharides in the FST, most likely because of the activation of GSK-3β by the inhibitor. In addition, naïve rats treated with oligosaccharides exhibited resistance to CUMS, accompanied by increases in the expression of BDNF, phosphorylated-Ser9-GSK-3β, and β-catenin in the medial PFC [251].

Moringa oleifera also produced significant changes in FST, TST, and LAT models, with the activity involving the noradrenergic-serotonergic systems [252]. In the case of Morus alba, it decreased immobility in the FST in rats, decreasing the HPA axis response to stress in the hippocampal and hypothalamic paraventricular nucleus region [253]. In contrast, the antidepressant-like activity (FST, TST, and CUMS in mice) of Mucuna pruriens involved the dopaminergic system [254]. Myristica fragrans also decreased the immobility period of mice in FST and TST models, with no effect on locomotor activity. Different selective inhibitors of monoamine activity/receptor/synthesis reduced or abolished the effects, which led to the hypothesis that the antidepressant-like effect of nutmeg is mediated by its interaction with the adrenergic (α1) and dopaminergic (D2) receptors, along with 5-HT synthesis [255]. Moinuddin et al. obtained similar results working with rats [256], but no mechanisms were proposed.

The activity of Nardostachys jatamansi was studied in silico. The docking results prompted the authors to propose that the compounds of this plant can modify depression through multiple molecular targeting of different compounds [257]. Other authors studied these compounds in vivo and observed that they produced a decrease in brain MAO-A and MAO-B activities, consequently increasing monoamine levels. In addition, the extract also interacted with GABA receptors, resulting in a decrease in GABA levels in the mouse brain [258]. Working with Nelumbo nucifera, researchers isolated the bisbenzylisoquinoline alkaloids neferine (68), liensinine (69), and isoliensinine (70, Fig. 7S, Supplementary Information), which were studied for their antidepressant-like activity (FST) in mice. The effect in this case was mediated by the 5-HT1A receptor, whereas other subtypes of 5-HT and adrenergic receptors (α1) were not implicated [259,260]. Extracts enriched in flavonoids, saponins, alkaloids, tannins, and terpenoids were also tested and likewise showed antidepressant-like activity in the FST as well as anxiolytic effects in the EPM, but no mechanisms were elucidated [261]. Ocimum tenuiflorum shortened the immobility time in both the TST and FST while also decreasing anxiety in different models but had no effects on the motor coordination of mice. No mechanisms or active compounds were proposed [262].

Panax ginseng has been used for generations in Asian countries to combat various maladies, including neurodegenerative diseases and cognitive dysfunctions [267]. It was shown to reduce immobility time in both the FST and TST [268]. The molecular and cellular mechanisms of ginseng include the modulation of the monoamine neurotransmitter system, the upregulation of the expression of neurotrophic factors, the regulation of HPA axis function, anti-inflammatory effects [269], and antioxidant activity through the Nrf2/heme oxygenase-1 system [270]. Several studies have focused on the pharmacological effects of different samples, such as the ginseng extract G115 [271], the sesquiterpene fraction [272], or saponins [273], which are the most relevant chemicals in the roots. The ginsenosides are the principal active group of chemicals found in this plant; of these, the ginsenoside Rg1 (9) has been shown to exert antidepressant-like effects in mice via activation of the hippocampal BDNF signaling pathway [274]. Indeed, treatment with ginsenoside Rb1 (10, Fig. 2S, Supplementary Information) attenuated the CUMS-induced decrease in the activities of BDNF, TrkB, Akt, ERK, and CREB in the mouse hippocampal CA3 region and PFC. These results suggest that BDNF-TrkB-CREB signaling may be involved in the antidepressant mechanism of the action of Rb1 [269]. This compound also exhibited a significant antidepressant-like effect in behavioral tests in mice (FST and TST), chronic animal models, and drug interactions. Its mechanism is mainly mediated by central neurotransmitters with a significant upregulation of 5-HT, NA, and DA levels in CUMS rat brains [275]. However, not only is the monoaminergic system implicated; the glutamatergic and GABAergic receptors may also be involved in the antidepressant-like effect of Rb1, mainly be-
cause ginsenoside Rb1 has been shown to up-regulate the levels of the monoaminergic and GABAAergic systems while decreasing the level of glutamate in the mouse hippocampus CA3 region and PFC [276]. Ginsenoside Rg1 (9) also modulated HPA and the hypothalamic-pituitary-gonadal axis in research carried out by Mou et al. [277], who proposed this new mechanism for the antidepressant-like effects of ginsenoside Rg1. The compound down-regulated serum corticosterone levels while increasing androgen receptor protein levels in the PFC of gonadectomized-treated mice, a result that provides theoretical clues for potential clinical therapies [277]. Another mechanism proposed for ginsenoside Rg1 is its effect on the corticosterone-induced gap junction intercellular communication dysfunction in astrocytes from the PFC and hippocampus, which may have clinical significance in the treatment of depression, as observed by Xia et al. [278]. With a chemical structure similar to that of ginsenoside Rg1, ginsenoside Rg5 (8, Fig. 25, Supplementary Information) likewise has anti-neuroinflammatory effects and leads to cognitive improvements. Xu et al. [279] studied the antidepressant-like effects of ginsenoside Rg5 using different models of depression. Ginsenoside Rg5 exhibited antidepressant-like activity in both the FST and TST without affecting locomotor activity. It was also effective in the CSDS model of depression, restoring the CSDS-induced decrease in the hippocampal BDNF signaling cascade. The authors thus concluded that ginsenoside Rg5 exerts its antidepressant activities via the activation of the hippocampal BDNF system [279]. Panax notoginseng has been used to achieve the same objectives as true ginseng. It is similar in composition, pharmacological make-up, and mechanisms for its effects [280]. For example, saponins found in the plant exerted antidepressant-like activity in CUMS, FST, and TST models through regulation of 5-HT, DA, and NA; modulation of GABA neurotransmission, the glutamatergic system, the HPA axis, and BDNF and its intracellular signaling pathways in the CNS; and by producing neuronal protection by means of anti-inflammatory, antioxidant, and anti-apoptotic effects [280, 281].

Paullinia cupana was assayed and compared with caffeine. It reduced the duration of immobility in the FST but had no effect on ambulation in the OFT. These results seem to indicate that the mechanism of guaraná does not involve the adenosinergic system [282]. Peganum harmala inhibited MAO-A due to its high content in the β-carboline alkaloids harmaline (71) and harmine (72, Fig. 75, Supplementary Information) [235]. Perilla frutescens oil reduced immobility time in an FST rat model, increasing both BDNF and 5-HT levels in the brain, thus partly explaining the antidepressant-like properties of this oil [283]. In contrast, the essential oil reversed the alterations in the concentrations of 5-HT and 5-HIAA and reduced the IL-6, IL-1β, and TNF-α levels in mice with CUMS-induced depression. The antidepressant-like activity in this case is related to the alteration of serotonergic responses and anti-inflammatory effects [284]. Phyllanthus emblica was tested with the FST and TST in mice; its observed activity may come about through its interaction with GABA, α1-, and D2-receptors, along with 5-HT synthesis [285]. Different species of Piper have been studied for their antidepressant-like effects in specific protocols in vivo and in vitro [286–291]. Piper laeticipicum was shown to decrease IL-6 and TNF-α (pro-inflammatory), upregulate the expression of BDNF mRNA, and downregulate caspase-3 mRNA [286]. An amide alkaloid, laetispicine (82, Fig. 85, Supplementary Information) decreased the immobility time (FST) [287], with a complementary study revealing another antidepressant-like compound identified as leatiispamide A (83, Fig. 85, Supplementary Information) [288]. Piper nigrum decreased swimming time while increasing immobility time in the FST; the mechanism involved attenuation of the oxidative stress in the rat amygdala [289]. Piper sarmentosum activity seems to be mediated by the modulation of the HPA axis along with phosphorylation and expression of BDNF, CREB, and ERK in the hippocampus [290]. Piplartine, (84, Fig. 85, Supplementary Information) an amide alkaloid, was isolated from Piper tuberculatum and shown to exhibit significant anxiolytic and antidepressant activities, but no mechanisms were proposed for the latter effect [291]. Other species of Piper, such as P. longum L. and P. methysticum have also been described as antidepressants [292].

The genus Polygala has 4 species with antidepressant-like properties, all of which have been tested by different authors using similar protocols (FST, OFT). In the case of Polygala paniculata, the activity was mediated by an interaction with the serotonergic (5-HT2A), adrenergic (α2 and β), and dopaminergic (D1 and D2) receptors [293], as occurs in the case of scopoletin (50, Fig. 65, Supplementary Information) isolated from Polygala sabulosa; however, in the latter case the effect involved the α1 but not the β-adrenoceptor [294]. In the case of Polygala sibirica, the activity was related to the normalization of the deficit in hippocampal neurogenesis with inhibition of newborn neuron apoptosis [295]. A mechanism similar for Polygala tenuifolia has likewise been cited [296], with a relevant role for the HPA axis, but in this species, researchers studied a particular isolated compound, 3,6'-disinapoyl sucrose (61, Fig. 65, Supplementary Information), and found that its antidepressant-like properties were mediated by the inhibition of MAO-A, MAO-B, the HPA axis, and the oxidative systems, all through increases in SOD activity, inhibition of lipid peroxidation, and decreases in the production of MDA [297]. The antidepressant effects of a mixture of α-aminergic (2) and β-aminergic (3, Fig. 15, Supplementary Information) isolated from Protium heptaphyllum were evaluated in the standard protocol of antidepressant-like effects, and their activity was attributed to a noradrenergic mechanism [298]. In contrast, the activity of Psychotropolum olacoides seems to be mediated by β-adrenergic and D1 receptors [299] along with the prevention of stress-induced HPA hyperactivity [300]. Pueraria montana var. lobata was tested against depressive-like behaviors of mice exposed to cerebral ischemia reperfusion and was found to modify the disturbance of DA and NA systems in both the hippocampus and striatum; this activity was more important in the development of depressive-like behavior in mice than that of the 5-HT system [301].

Rhazya stricta [302, 303], along with Rosa × damascena [304, 305] were both studied and found to possess antidepressant properties. There are many papers on the potential of Rosmarinus officinalis as an antidepressant drug, but no relevant clinical studies have been performed. Machado et al. [306] observed a marked antidepressant-like effect in mice (FST and TST). Pretreatment with a 5-HT synthesis inhibitor and receptor antagonists (5-HT2A, 5-HT1, α1, D1, and D2)—but not with an α2-adrenoceptor antago-
nist-reversed the anti-immobility effect. The authors concluded that the antidepressant effect of rosemary is mediated by an interaction with the monoaminergic system. These same authors [307] established the effect of this extract in olfactory bulbectomized mice, observing an increase in hippocampal AChE activity. They hypothesized that rosemary extract could thus be used in the treatment of depression [307]. In 2 complementary studies, these same researchers established that the potential active compounds of this extract, tested in the same protocols, were ursolic acid (4) [308], betulinic acid (5) (Fig. 15, Supplementary Information), and carnosol (25, Fig. 3S, Supplementary Information), [309]. However, other authors have cited luteolin (28, Fig. 4S, Supplementary Information), carnosic acid (26, Fig. 3S, Supplementary Information), and rosmarinic acid (58, Fig. 6S, Supplementary Information) as potential active compounds because they were shown to regulate DA, NA, 5-HT, and ACh, as well as the gene expression of tyrosine hydroxylase and pyruvate carboxylase, 2 major genes involved in dopaminergic, serotonergic, and GABAergic pathway regulation [310]. Rosmarinic acid, luteolin-7-O-glucuronide (39, Fig. 5S, Supplementary Information), and caffeic acid (48, Fig. 6S, Supplementary Information), all of which are AChE inhibitors [311], as well as salvigenin (29), cirsimaritin (30, Fig. 4S, Supplementary Information), and rosmanol (27, Fig. 3S, Supplementary Information), which produce biphasic modulation of GABA<sub>A</sub> receptors [312], have also been proposed as active constituents. In one interesting study, Guo et al. [313] investigated the antidepressant effects of rosemary extracts on chronic restraint stress mice along with the inflammatory mechanisms related to the gut microbiome. The results showed that the extract significantly ameliorates depressive-like behaviors in chronic restraint stress mice. This effect was due to the inhibition of inflammatory reactions in the hippocampus and serum, as well as in microglia cells (BV-2), and the promotion of BDNF and p-Akt/Akt expression in the hippocampus, along with a rebalance of gut microbiota. This data is of interest because there is a clear relationship between depression and abundance of Lactobacillus, Bacteroidetes, Firmicutes, and Proteobacteria. The rosemary extracts were found to decrease the proportion of both Bacteroidetes and Proteobacteria while promoting an abundance of Lactobacillus and Firmicutes. With respect to the pro-inflammatory mediators, the extract reduced IL-1β, TNF-α, and p-NF-κB, indicating a protective effect for rosemary extract in mice and its implication in the anti-depressant-like properties of the plant [313]. A lipid extract (D-004) of Rosytonoe regia increased mouse immobility in both the FST and TST but showed no effects in other behavioral tests [314].

Three species of <em>Salvia</em> have been tested as potential antidepressant-like agents in rodents. Salvinorin A (23, Fig. 3S, Supplementary Information), the major compound from <em>Salvia divinorum</em>, was isolated and tested in EPM, FST, and TST rodent models. The authors concluded that the anxiolytic- and antidepressant-like effects of salvinorin A are mediated by both opioid and endocannabinoid systems but that the compound had a very weak affinity for cannabinoid CB<sub>1</sub> receptors [315]. <em>Salvia elegans</em> was also tested, but no significant activities were described [316]. In the case of <em>Salvia sclarea</em>, the essential oil showed antidepressant-like effects in the FST in rats. This property seems to be closely associated with modulation of the dopaminergic pathway [317]. <em>Sceletium tortuosum</em> is also used as an antidepressant, with different studies in animals demonstrating its activity [318–320]. The active compounds have been identified as mesembrine alkaloids [321]. Of these, both mesembrine (74) and mesembrenone (75, Fig. 7S, Supplementary Information) are 5-HT<sub>2</sub> receptor inhibitors, but mesembrenone also has a reasonably potent inhibitory effect on phosphodiesterase-4 [321] while mesembrine was shown to be the most active alkaloid against SERT [322]. While this species has antidepressant properties, it also produces ataxia, which may limit its usefulness as an antidepressant [318]. The activity of <em>Schinus molle</em> was shown to be due to its interaction with the serotonergic (synthesis and 5-HT<sub>1A</sub>, 5-HT<sub>2A/2C</sub>, 5-HT<sub>3</sub> receptors), noradrenergic (α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors), and dopaminergic (D<sub>1</sub> and D<sub>2</sub> receptors) systems. Although the extract contains triterpenoids as major compounds, no principles specifically responsible for these effects have been identified. Further chemical analysis of the extract is planned in order to isolate and characterize the active compounds responsible for the observed effects [323]. In addition, rutin (45, Fig. 5S, Supplementary Information) was also tested, and authors justified that the antidepressant-like effect of <em>Schinus</em> molle was due to rutin, which acts by increasing the availability of 5-HT and NA in the synaptic cleft [324]. <em>Schisandra chinensis</em> produces an antidepressant-like effect in corticosterone-induced depression in mice; the effect seems to be mediated by the modification of the stress-based HPA axis dysfunction and upregulation of the BDNF/TrkB/CREB signaling pathway [325, 326] along with the PI3K/Akt/GSK-3β pathways [326]; however, the modification of noradrenergic, dopaminergic, GABAergic, and glutamatergic systems may also play a role [327]. <em>Scrophularia ningpoensis</em> has also been described as an antidepressant-like medicinal plant in an LHT model of depression [328]. <em>Scrophularia striata</em> exerts its anxiolytic and antidepressant effects through modulation of the GABAergic system, most probably GABA<sub>A</sub>, as was demonstrated in EPM and FST models, as well as through modulation of the intracerebroventricular administration of an agonist or antagonist, which was shown to enhance or block the effect of the ethanol extract [329]. <em>Scutellaria baicalensis</em> reduced immobility time (FST and TST), increased sucrose consumption (SPT), alleviated the damage from CUMS-induced neurogenesis, and improved depressive-like behavior through the regulation of the cAMP/PKA neurogenesis pathway. The authors identified wogonin (31), baicalin (32, Fig. 4S, Supplementary Information), baikalin (42), and wogonoside (43, Fig. 5S, Supplementary Information) as the principal compounds responsible for these effects [330]. Of these, baikalin has been studied as an isolated compound and was shown to increase sucrose consumption in the SPT as well as the number of crossings in the OFT. It also attenuated immobility time in the TST, with its mechanism seemingly related to the promotion of neuron differentiation via the Akt/FOXG1 pathway [331]. In addition, baikalin increased DA levels in the rat striatum, hippocampus, and cortex and ameliorated the synaptogenesis associated with GABA<sub>A</sub> receptor downregulation following abnormal stimulation of D<sub>1</sub> receptors [332]. <em>Securidaca longepedunculata</em> probably exerts its antidepressant-like effects through the opioidergic pathway [333].

<em>Sedum roseum</em> is used as an adaptogen, antidepressant, and anti-inflammatory agent [334–336]. A wide variety of preclinical
in vivo and ex vivo studies with laboratory animals suggests the presence of several biochemical and pharmacological antidepressant-like actions [337]. Different studies in animals established that golden root extract and its principal constituent, salidroside (59, Fig. 6S, Supplementary Information), interact with different mediators implicated in several molecular networks of the neuroendocrine and neurotransmitter systems involved in the pathophysiology of depression. It was shown to improve depressive-like behaviors through its anti-inflammatory effects (reducing TNF-α and IL-1β levels in the hippocampus) and the regulation of HPA axis activity (increasing glucocorticoid receptor and BDNF expression in the hippocampus, attenuating CRH expression in the hypothalamus, and reducing corticosterone in serum) in olfactory bulbectomized rats [338]. In summary, the principal targets and pathways that have been established for these extracts are the CREB/microphthalmia-associated transcription factor/tyrosinase pathway, the 5-HT/5-HT1A receptors, and MAO (FST and TST) [347]. In the former, the α2-adrenoceptors are probably responsible for the plant’s antidepressant-like effects as observed in both the FST and TST [341]. As for the latter species, different analogs of the natural piperidine alkaloid (-)-3-O-acetylspectaline isolated from it were studied for their antidepressant-like activities. In the end, the derivative ethyl 2-[(3-nitropyridin-2-yl)sulfonyl]acetate was shown to decrease the immobility time of mice in the FST without affecting locomotor activity; unfortunately, no mechanism was proposed [342]. *Sida tiagii* showed activity in the FST and TST, acting through the inhibition of both MAO (more selectively in MAO-A than on MAO-B) and lipid peroxidation [343]. *Siphocampylus verticillatus* was also studied for its potential antidepressant-like effect in 2 models in mice and against synaptosomal uptake of 5-HT, NA, and DA. The authors concluded that the extract elicited its antidepressant-like effect through interaction with the adrenergic, dopaminergic, glutamatergic, and serotonergic systems [344]. *Solomon torvum* inhibited the immobility period (FST and TST), increased DA, NA, and 5-HT levels, and inhibited MAO in mice [345]. In a second study, these same authors examined the effect of torvanol A (36, Fig. 4S, Supplementary Information), and found that it likewise decreased the immobility period in the specific tests through implication of the noradrenergic, dopaminergic, serotonergic, and GABAergic systems [346]. In another study, *Sonchus oleraceus* reduced the immobility time in the FST and TST [347].

Two species of *Tagetes* have been studied by various researchers. *Tagetes erecta* inhibited the immobility period in mice (FST), with the serotoninergic and nitrergic pathways, as well as the α-opioid receptors, all being implicated in the antidepressant-like activity [348]. *Tagetes lucida* reduced immobility and increased swimming without affecting climbing behavior in the FST; in addition, it affected neither motor activity nor male sexual behavior in rats, which may explain its antidepressant-like properties [349]. The effect seems to be mediated by the serotonergic system [350] and is blocked by HT2A receptor antagonists and serotonin synthesis inhibitors but not by β- and α2-noradrenergic receptor antagonists, indicating that the extract modulates the release/reuptake of serotonin [351]. *Tanacetum parthenium* has exhibited anxiolytic and antidepressant-like effects in various tests, prompting the authors to propose the involvement of the GABAergic system [352]. *Terminalia bellirica* exerted its antidepressant-like effects (FST and TST) in mice through interaction with the adrenergic (α1), dopaminergic (D2), and serotonergic (release/reuptake of 5-HT) systems [353]. In the case of *Theobroma cacao*, the antidepressant-like effect of the polyphenol-enriched extract was studied and justified in part by the antioxidant effects of its polyphenols; however, the high amount of magnesium found in the extract could also be implicated, as this mineral has been reported to be effective against depression-like behavior in mice [354]. The methanol extracts and essential oils from the aerial parts of 3 species of *Thymus*—*T. fallax*, *T. kotschyanus*, and *T. pubescens*—were studied in mice, with all 3 species shortening the duration of immobility in the FST. In addition, the activities of the essential oils were lower than those of the extracts, with both the extracts and oils of *T. fallax* being more active than those of *T. kotschyanus* and *T. pubescens* [355]. The effect of *T. kotschyanus* extract was corroborated in FST and TST mouse models by Doosti et al. [356]. *Tinospora sinensis* produced a significant antidepressant-like effect in both the FST and TST, acting through the α2-adrenoceptor, D2 receptor, 5-HT release/reuptake, and GABAb reduction while also reducing MAO-A and MAO-B levels overall in mice, leading to an increase in brain monoamine levels [357]. In a preliminary study, Campos et al. [358] described the antidepressant-like effects of *Trichilia catigua* in rodents (FST), inhibiting the uptake and increasing the release of both 5-HT and DA from rat brain synaptosomes [358]. The content in simple phenolics and tannins could explain this effect as they exert a strong antioxidant activity [359]. In a complementary study, Bonassoli et al. [360] likewise observed antidepressant-like effects along with the induction of hippocampal cell proliferation in mice for this same extract, whereas Bernardo et al. [361] demonstrated that the aqueous extract of the bark of this plant inhibited MAO-A and AChE activities, inhibiting the xanthine/xanthine oxidase pathway and throwing the oxidative stress out of equilibrium by acting as a SOD anion radical scavenger, which may account for its antidepressant-like effects. In a screening for antidepressant and anti-anxiety plants, 17 plant species were tested for their affinity to the 5-HT transporter and for inhibition of MAO-A. Of these, *Trigonella foenum-graecum* was the most active in the MAO-A assay, with no effect on 5-HT reuptake [362]. This property was subsequently confirmed by Khursheed et al. [363] with a similar extract, which exhibited activity in the FST and TST but not in the OFT, reducing both MAO-A and MAO-B. In addition, the flavonoid-enriched extracts from the seeds of this plant were shown not only to reverse the CRS-induced behavioral abnormalities but also to restore the induced changes in serum levels of corticosterone, as well as those of the neurotransmitters DA, NA, and 5-HT in the PFC and hippocampus, and those of NA in striatum. The extract also inhibited MAO-A activity as well as downregulating the KLF11, SIRT1, and MAO-A protein expression levels in the PFC and hippocampus. These results justify the role of flavonoids in the antidepressant-like effects of this species [364]. *Uncaria lasosa var. appendiculata* was assayed
in FST and TST mouse models, increasing the levels of 5-HT and 5-HIAA in the cortex, striatum, hippocampus, and hypothalamus, as well as increasing NA levels in the cortex, hippocampus, and striatum along with the 4-dihydroxyphenylacetic acid levels in striatum [365].

Grouped under the common name of valerian, there are about 200 known species of the genus Valeriana, but V. officinalis is the most commonly used for medicinal purposes and the only one accepted by the European Medicines Agency to treat insomnia as a sedative-hypnotic, as well as for its anxiolytic, antidepressant, and anticonvulsant properties [366]. Valerian roots contain volatile oils and the iridoids known as valepotriates (valtrate, 21, Fig. 3S, Supplementary Information). Hattesohel et al. [367] carried out various experiments with 4 commercially available preparations on mice and rats, finding anxiolytic and antidepressant activities but not sedative or myorelaxant properties. The extracts increased BDNF levels in vitro, an effect that was completely reversed after removal of valeranic acid (22, Fig. 3S, Supplementary Information) from the extract, indicating that this compound is crucial for the neuronal activity [368]. Three other species of Valeriana were also tested: V. fauriei [369, 370], V. glechomifolia [371–373], and V. jatamansi [374]. In the first species, bicyclo[8,1,0]5β-hydroxyl-7β-1acetoxyl-5,11,11′-trimethyl-E-1(10)-ene-4,15-olide was identified as the principal active compound, increasing the immobility time in the FST in mice [369]. The extract enhanced the stimulation of Nrf-2 pathways, in accordance with upregulation in protein expression of BDNF [370]. In the second assay, a supracritical CO2 extract enriched in valepotriates was tested in TST and FST models and showed an anti-immobility effect that was reversed by both the α2-adrenoceptor antagonist and D1 and D2 receptor antagonists, whereas neither α1-adrenoceptor antagonists nor serotonin synthesis inhibitors had any effect on the anti-immobility effect of the extract. These results account for the antidepressant-like activity of valepotriates through their interaction with dopaminergic and noradrenergic neurotransmission [371]. The synergistic interactions between diene valepotriates (valtrate, acelvaltrate, 1-β-acelvaltrate, 1-β-aceacevaltrate, and isovaltrate) and various standard antidepressants highlight their potential as adjuvants because they target different neuronal transporters than those targeted by standard treatments [372]. Moreover, the activity of diene valepotriates in the FST was reduced by a protein synthesis inhibitor that works by inhibiting Trk receptors, which could explain the role of diene valepotriates in the extract’s antidepressant-like activity, namely through its reduction of hippocampal DNA methylation together with increased protein synthesis. Furthermore, BDNF-mediated Trk signaling also contributes to the antidepressant-like effect of this extract [373]. In the third case, the extract increased DA and NA levels in the forebrain [374].

Vanda spathulata inhibit both MAO-A and MAO-B in mouse brains in both the FST and TST [375]. Three flavonoids were isolated from Viola odorata and tested in mice (TST and FST) to compare their antidepressant-like effects with those of the standard drug, fluoxetine. The compounds were identified as 5,7-dihydroxy-3,6-dimethoxyflavone (33), 5,7,4-trihydroxy-3′,5′dimethoxyflavone (34), and 5,7,4-trihydroxy-3′-methoxyflavone (35, Fig. 4S, Supplementary Information); all exhibited activity on 5-HT1A, 5-HT2A, and 5-HT3 receptors but not on D1 and D2 receptors. There was likewise no effect on 5-HT synthesis, indicating that the antidepressant-like effects involve the serotonergic system [376].

A glycowithanolide-enriched fraction from Withania somnifera exhibited antidepressant effects in the FST in rats [377]. Shah et al. [378] tested an extract of ashwagandha alone as well as in combination with standard drugs; in both cases, imipramine and fluoxetine produced a significant decrease in the mean immobility time in the FST, an effect that seems to be mediated partly through the α-adrenoceptor and alterations in the levels of central biogenic amines [378]. Ashwagandha also exhibited anxiolytic effects in the EPM [379] as well as anti-inflammatory and antioxidant properties [380], which may strengthen its antidepressant-like effects. Xylopia aethiopica showed antidepressant-like properties through its effects on 5-HT neurotransmission, but also by a synergistic effect with the glycineB receptor (possible glutamatergic effect) and NOS inhibition. The adrenergic system was not involved, as indicated by the fact that catecholamine depletion did not affect the antidepressant properties [381]. In the case of Xylopia malobiyum undulatum, the extract showed activity in mice but not in rats (FST). Moreover, it showed affinity to SERT, but, when used at a different concentration, had no effect on SERT, NAT, or DAT transporters, indicating that the effects are most likely due to another mechanism [41]. In one early study on Zingiber officinale, Sharma et al. [382] described the effect of the ethanol extract in different CNS tests, including the FST and TST, in which it was shown to decrease time of immobility; this effect was related to its antioxidant properties. Martinez et al. [383] isolated and studied a phenolic from the rhizomes, dehydrozingerone (85, Fig. 8S, Supplementary Information), which showed antioxidant activity in the hippocampus, cortex, and cerebellum of mice, as analyzed in TST and FST models, reducing the immobility time in both tests with no concomitant effect on locomotor activity in the OFT. Its activity involved 5-HT2A/2C and 5-HT3 receptors, as well as α1- and α2-adrenoceptors. The antidepressant-like effect of ginger thus involves the serotonergic and noradrenergic systems as well as its antioxidant properties [383]. However, in a study by Kukula-Koch et al. [384], the nonpolar fraction of the oleoresin was as also found to possess antidepressant activities. Of the different principles, (−)-geraniol (16) and (−)-terpinen-4-ol (17, Fig. 1S, Supplementary Information) were found to be the strongest MAO-A inhibitors [384].

Finally, although other species have been previously described, no studies on them have been conducted since the year 2000, and, in many cases, the protocols and mediators have never been described. The principal species in this category are true cinnamon tree (Cinnamomum verum J.Presl, syn: Cinnamomum zeylanicum Blume, Lauraceae) [28], bindweed (Cissampelos sympodiadis Eichler, Menispermaceae) [292], Indian coleus (Coleus forskohlii (Willd.) Briq., Lamiaceae) [292], dodder (Cuscuta sp., Convolvulaceae) [12], red feathers (Echium amoenum Fisch. & C.A.Mey., Boraginaceae) [24, 27, 292], common water hyacinth (Eichhornia crassipes (Mart.) Solms, Pontederiaceae) [28, 29], “arina roja” (Galphimia glauca Cav., Malpighiaceae) [24], Levant cotton (Gossypium herbaceum L., Malvaceae) [292], imperforate St john’s wort (Hypericum maculatum Crantz, Hypericaceae) [29], “xuan fu hua” (Paeonia lactiflora Pall., Ranunculaceae) [368, 374], and “xian xing che” (Hibiscus mutabilis L., Malvaceae) [368, 374].
hua" (Inula japonica Thunb., Compositae) [292], Thai black ginger (Kaempferia parviflora Wall. ex Baker, Zingiberaceae) [292], Indian tobacco (Lobelia inflata L., Campanulaceae) [25, 292], houpu magnolia (Magnolia officinalis Rehder & E.H.Wilson, Magnoliaceae) [23, 25, 292], “gondolosi” (Mondia whitei (Hook.f.) Skeels, Apocynaceae) [41], evening-primrose (Oenothera biennis L., Onagraceae) [23], wild maraucja (Passiflora foetida L., Passifloraceae) [29], musk willow (Salix aegyptiaca L., Salicaceae) [28], “sanjeevani” (Selaginella bryopteris (L.) Baker, Selaginellaceae) [29], “dhigu-thiyara” (Senna occidentalis (L.) Link, syn: Cassia occidentalis L., Leguminosae) [29], wild marigold (Tagetes minuta L., Compositae) [25], yellow trumpetbush (Tecoma stans (L.) Juss. ex Kunth, Bignoniaceae) [29], common nettle (Urtica dioica L., Urticaceae) [29], common grape vine (Vitis vinifera L., Vitaceae) [292], and “katber” (Ziziphus xylopyrus (Retz.) Rhamnaceae) [385]. Species such as Eysenhardtia polystachya (Ortega) Sarg. (Leguminosae) [386], Capparis brosii DC (syn: Capparis thonninii Schumach., Capparaceae) [387], and Cnestis ferruginea Vahl ex DC (Conaraceae) [388] could also be of interest for antidepressant studies.

**Concluding Remarks**

The purpose of this narrative review has been to provide an update on the medicinal plants studied from the year 2000 to the present. It includes approximately 660 preclinical studies cited in PubMed in which 155 species have been shown to have some kind of effect. An additional 27 species had also been previously described, but no new studies on them have been undertaken.

Animal models have provided significant information on the pathophysiology of depression, although they are insufficient for explaining depressive syndrome in all its complexity due to obvious differences in genetics and pharmacokinetics. Moreover, and perhaps more importantly, animals cannot provide information regarding core symptoms of depression such as depressed mood, suicide ideation, low self-esteem, feelings of worthlessness, and excessive or inappropriate guilt. However, depression and other related disorders involve several endophenotypes [31] that can be approached separately with different animal tests to also provide important evidence regarding the potential activity of medicinal plants as antidepressant agents. On the one hand, the FST and TST are the 2 principal animal models measuring behavioral distress in mice and/or rats. On the other hand, the SPT aims to cover the endophenotype of anhedonia, while the CUMS test, along with other complementary tests such as the OFT and EPM, are validated models for behavior related to anxiety. In the case of the FST and TST, the immobility time was selected as the dependent variable, and its decrease was used to establish the potential of a drug or pharmacological agent as an antidepressant. These results were then combined with the lack of locomotor activity as determined in the complementary tests. In general, many preclinical studies of species tested as antidepressant agents focused on the neurotransmission role of DA, NA, and 5-HT, especially in the involvement of the α1-adrenoceptor, D1 and D2 receptor antagonists, and the 5-HT1A receptor. Moreover, the effects of selective 5-HT reuptake inhibition and the inhibition of SERT, NAT, and DAT as a target to ameliorate depressive symptoms have been explained by the monoaminergic theory of depression, based on the assumption of a lack of monoamine neurotransmitters in depressive patients. Today, antidepressants that have been developed according to this theory constitute the “first line of treatment”, although they have documented issues, namely a mere 60% response rate, a therapeutic latency of 2 or 3 wk, important side effects, and a major relapse risk if treatment is not continued [389].

The expression of BDNF in the brain has also been postulated as a core explanation for depression by the neurotrophic or neuroplasticity hypothesis. According to this theory, mood disorders are related to a decreased synthesis of BDNF in the brain due to a deficiency of neurotrophic factors, producing a subsequent impairment in synaptogenesis and neuronal activity. Medicinal plants can act to prevent the decreases in hippocampal BDNF signaling observed in depression, promoting neurogenesis in mice, an effect that could be considered an antidepressant-like mechanism [63]. Plasticity enhancements (e.g., neurogenesis, dendritic branching, and synaptogenesis) have antidepressant effects promoting BDNF secretion in the brain; even an increase in serum is associated with recovery [390]. Electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct-current stimulation, and ketamine and its derivatives have demonstrated some efficacy as therapies for depression [391]. In contrast, stress and other risk factors for depression can reduce neuroplasticity in the hippocampus and PFC [392]. Therefore, it seems reasonable to hypothesize a common pathway underlying the pathogenesis and vulnerability to depression. However, there are still some gaps underlying molecular mechanisms of neuroplasticity, depression, and antidepressant efficacy, particularly the interaction between neurotransmitter receptors and their signaling pathways. Thus, the neuroplasticity hypothesis has unfortunately not yet been validated clinically although many of the benefits of antidepressant treatments that work lead to it.

Depression also involves dysfunctional glutamate signaling in the brain, which leads to impaired neuroplasticity. Microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain, potentially leading to depression [392]. Moreover, we must take into account the spectacular clinical finding that i.v. infusion of the NMDA receptor antagonist ketamine can produce an immediate antidepressant effect in patients with treatment-resistant depression [393]. Therefore, it seems reasonable that one of the targets in the treatment of depression is to down-regulate the glutamatergic system. Glutamatergic inhibition in nerve terminals through the exposure of synaptosomes to the K+ channel blocker 4-aminopyridine is one of the known antidepressant mechanisms of action of curcumin [394]. Other antiglutamatergic agents such as amantadine, ketamine, memantine, and riluzole have also demonstrated antidepressant properties [392, 395]. The neuroprotective effects of ketamine and memantine may be explained by their NMDA antagonism, which inhibits microglial release of pro-inflammatory mediators, avoiding neurotoxicity. How this occurs is not completely known yet.

The GABAergic system also plays a relevant role in depression [396], which could have a potential additive effect on motor activity, as well as on both neuro-endocrine (HPA axis, CRF) and, im-
portantly, neuroprotective effects, in the same way that antiglutamatergic mechanisms do.

Other additional hypotheses on the pathogenesis of depression are based on the modulation of cholinergic transmission, the stress/HPA-axis, the reward system, and neuroinflammation. It is known that inflammation leads to increased permeability of the brain-blood barrier, allowing for easier entry of inflammatory molecules or immune cells into the CNS, leading to both structural and functional changes, with the hippocampus as the main structure affected [397]. On the other hand, physiological or psychological conditions that cause a strong activation of the immune system make patients more susceptible to depression [398]. These facts have increased both the interest in and the corpus of studies of those medicinal plants with anti-inflammatory and antioxidant properties, as well as the mediation of pro-inflammatory factors, mitochondrial damage, and oxidative stress in neuronal damage (e.g., *Curcuma longa*, *Cinkgo biloba*, Panax ginseng, Rosmarinus officinalis, and Sedum roseum). It thus seems clear that depression activates inflammatory processes and interacts with the immune system through biochemical and bio-behavioral mechanisms, although more research is needed.

According to the data compiled in this paper, use of medicinal plants in combating depression would offer at least 3 benefits. First, an increasing amount of evidence indicates that these plants exert antidepressant effects on their own, as is the case with green tea (*Camellia sinensis*), saffron (*Crocus sativus*), St. John’s wort (*Hypericum perforatum*), lavender (Lavandula angustifolia), Indian mulberry (Morinda officinalis), ginseng (Panax ginseng), rosemary (Rosmarinus officinalis), golden root (Sedum roseum), ashwagandha or Indian ginseng (Withania somnifera), and especially turmeric (*Curcuma longa*) and its active principle curcumin. Other potentially effective plants that should be tested, including in humans, are jack-beans from Brazil (*Canavalia brasiliensis*), gotu kola (*Centella asiatica*), Asian pigeonwings (*Clitoria ternatea*), Siberian ginseng (*Eleutherococcus senticosus*), and Indian mulberry (*Morinda officinalis*). We strongly recommend carrying out larger experimental studies on the active compounds of these plants and their mechanisms of action, as well as clinical studies and randomized controlled trials of many of them. Regarding cannabis (*Cannabis sativa* L., Cannabinaceae), various articles have been published demonstrating its antidepressant-like activity [399-401], with cannabinol as the principal active compound and serotonergic (5-HT1A) [399,400] and BDNF-TrkB signaling pathways [401] as the principal mechanisms. However, due to its relevance, this species will be treated more fully in the second part of this review (clinical trials).

Recent research has shown that adjunctive treatment can increase the efficacy of standard treatments for depression, such as using ketamine with SSRIs or buprenorphine and sanidorphan [389]. This provides a second benefit for medicinal plants, namely that they can be co-prescribed in combination with standard pharmacological agents; for example, St. John’s wort can enhance the serotonergic effects of SSRIs [12]. If the combination produces beneficial synergistic effects, then a lower dosage of antidepressants can be used to prevent or avoid undesirable side effects in patients who frequently exhibit them, thereby obtaining a third benefit. Of course, the opposite can also occur, namely, an increase in adverse side effects. Therefore, we strongly recommend caution as a rule since larger and more robust studies are needed to explore these synergies.

There are several limitations of the studies compiled in this revision, including the wide range of dosages, the different solvents used to obtain the extract, and the use of distinct vegetable products, including roots, leaves, stems, or the use of enriched extract. Another limitation is the great variety of the animal models used. Although these are designed to capture a specific endophenotype of depression, it is impossible for one of them to encompass the tremendous heterogeneity of depressive behavior. Regarding the limitations that the lack of an integrative explanation regarding the pathophysiology of depression represents for this review, the preclinical data explored herein aims to be a starting point for encouraging robust research to test the most promising medicinal herbs, such as turmeric and its active compound curcumin, along with saffron.

We must not forget the large number of patients who do not experience total or even partial remission of their depressive symptoms. They deserve alternative or complementary treatments that could relieve their suffering and lower the incidence of suicidal ideation and attempts, thereby helping their families cope with the depression of their loved ones and consequently decrease their distress.

There is an immense number of targets to help alleviate the tremendous burden that depression causes worldwide, and despite the limitations of the current research and the challenges of conducting large clinical trials in the future, medicinal plants have much to offer in the field of antidepressant treatments and adjuvants.

**Supporting Information**

This section consists of a table with all the medicinal plants cited in the text, with the updated botanical and family name, the common name, the plant part and kind of extract used in the studies, the range of doses used in mg/kg and via of administration, potential active compounds, neurochemical pathways implicated in the process, and references. The figures compile the principal chemical products identified as being responsible for this activity if they were clearly identified or studied as potential active principles.

**Contributors’ Statement**

Both authors have participated in the preparation of the document jointly.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**References**


[54] Sousa FC, Melo CT, Monteiro AP, Lima VT, Gutierrez SJ, Pereira BA, Barbosa-Filho JM, Vasconcelos SM, Fontes MF, Viana GS. Anxioty and antidepressant effects of riparin III from Aniba riparia (Nees) Mez (Lauraceae) in mice. Pharmacol Biochem Behav 2004; 78: 27–33


Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 2012; 26: 1512–1524


Xu Y, Ku B, Li L, Li X, Barish PA, Foster TC, Ogle WO. Curcumin reverses impaired hippocampal gene expression and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007; 1162: 9–18


Yi LT, Li J, Li HC, Zhou Y, Su BF, Yang KF, Jiang M, Zhang YT. Ethanol extracts from Hemerocallis citrina attenuate the decreases of brain-derived neurotrophic factor, TrkB levels in rat induced by corticosterone administration. J Ethnopharmacol 2012; 144: 328–334


Butterweck V. Mechanism of action of St John’s wort in depression. CNS Drugs 2003; 17: 539–562


Viana A, Rates S, Naudin B, Janin F, Costentin J, de Rego JC. Effects of acute or 3-day treatments of Hypericum confopila- tum Cham. & Schlcht. (Guttiferae) extract or of two established antidepressants on basal and stress-induced increase in serum and brain corticosterone levels. J Psychopharmacol 2008; 22: 681–690


Weng L., Dong S., Wang S., Li L., Geng D. Macranthol attenuates lipopolysaccharide-induced depressive-like behaviors by inhibiting neuroinflammation in prefrontal cortex. Physiol Behav 2019; 204: 33–40


Galdino PM., Carvalho AAV., Florentino MD., Martins JLR., Gazola AC., de Paula JR., de Paula JAM., Torres LMB., Costa EA., de Lima TCM. Involvement of monoaminergic systems in the antidepressant-like properties of *Lavandula officinalis* A. St. Hil. J Ethnopharmacol 2015; 170: 218–225


Audi EA. Effect of xanthone from *Marsilea minuta* leaves on anxiety, depression and memory. Avicenna J Phym Med 2016; 6: 966–970


Ishola IO., Akinwale MA., Sholarin AM. Antidepressant and anxiolytic properties of the methanolic extract of *Momordica charantia* Linn (*Cucurbitaceae*) and its mechanism of action. Drug Res (Stuttg) 2014; 64: 368–376


Li YF., Gong ZH., Yang M., Zhao YM., Luo ZP. Inhibition of the oligosaccharides extracted from *Morinda officinalis*, a Chinese traditional herbal medicine, on the corticosterone induced apoptosis in P12 cells. Life Sci 2003; 72: 933–942


Lim DW., Kim YT., Park JH., Baek NI., Han D. Antidepressant-like effects of the ethyl acetate soluble fraction of the bark root of *Morus alba* on the immobility behavior of rats in the forced swim test. Molecules 2014; 19: 7981–7989

Rana DG., Galani VJ. Dopamine mediated antidepressant effect of *Mucuna pruriens* seeds in various experimental models of depression. Ayu 2014; 35: 90–97

Dhingra D., Sharma A. Antidepressant-like activity of *n*-hexane extract of nutsmeg (*Myristica fragrans*) seeds in mice. J Med Food 2006; 9: 84–89


of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 421–428


[333] Moragrega I, Ríos JL. Medicinal Plants in... Planta Med | © 2021. Thieme. All rights reserved.


Shah PC, Trivedi NA, Bhatt JD, Hemavathi KG. Effect of Withania somnifera on forced swimming test induced immobility in mice and its interaction with various drugs. Indian J Pharmacol 2006; 50: 409–415

Gupta GL, Rana AC. Protective effect of Withania somnifera dural root extract against protracted social isolation induced behavior in rats. Indian J Pharmacol 2007; 51: 345–353


Ishola IO, Olayem SO, Yemitan OK, Umezeh EA. Antidepressant and anxiolytic effects of the methanol root extract of Capparis thonningii: Involvement of monoaminergic, cholinergic and GABAergic systems. Drug Res (Stuttg) 2015; 65: 205–213


[400] Sales AJ, Crestani CC, Guimarães FS, Joca SRL. Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels. Prog Neuropsychopharmacol Biol Psychiatry 2018; 86: 255–261